SCHEMBL23705892

SCHEMBL23705892

O=C(O)NCc1cc(/C(F)=C(\F)c2ccccc2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 2/20 0.48
KDM4B O94953 2/20 0.48
KDM5C P41229 2/20 0.48
KDM5B Q9UGL1 2/20 0.48
SMN1; SMN2 Q16637 5/20 0.43
GAA P10253 2/20 0.43
KMT2A Q03164 3/20 0.42
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
POLB P06746 3/20 0.42
LMNA P02545 1/20 0.42
KDM4E B2RXH2 2/20 0.40
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK14 Q16539 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 2/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23706062 0.82 ACACB (0.48) KDM4AKDM4BKDM5CKDM5BSMN1; SMN2
SCHEMBL509374 0.79 KDM5B (0.50) KDM4AKDM4BKDM5CKDM5BSMN1; SMN2
SCHEMBL23706030 0.77 CYP1A2 (0.39) KDM4AKDM4BKDM5CKDM5BSMN1; SMN2
SCHEMBL23705944 0.75 NR3C2 (0.55) KDM4AKDM4BKDM5CKDM5BSMN1; SMN2
SCHEMBL22581521 0.73 KMT2A (0.49) SMN1; SMN2KMT2ANPC1RAB9AHPGD
SCHEMBL243740 0.73 SMN1; SMN2 (0.76) SMN1; SMN2GAAKMT2ANPC1RAB9A
SCHEMBL30602600 0.73 SMN1; SMN2 (0.76) SMN1; SMN2GAAKMT2ANPC1RAB9A
SCHEMBL21437557 0.72 RAB9A (0.48) SMN1; SMN2KMT2ANPC1RAB9APOLB
SCHEMBL3475219 0.72 SMN1; SMN2 (0.49) KDM4AKDM4BKDM5CKDM5BSMN1; SMN2
SCHEMBL16991863 0.72 RECQL (0.46) KDM4AKDM4BKDM5CKDM5BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KDM4A 2166/4885KDM4B 1679/4885KDM5C 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.